4/19/2024How BIO CEO's Cozy Relationship with WuXi Soured (STAT)

4/19/2024China's Drugmakers Can't Sell mRNA Shots But Haven't Quit Yet (Reuters...

4/17/2024A Risky Bet: Zai Lab's Uncertain Future (Seeking Alpha)

4/16/2024America Hits Chinese Biotech — And Its Own Drugmakers (Economist)

4/15/2024The Pharmaceutical Playbook for Asia’s Private Market (PharmExec)

4/15/2024China Biopharma Tracker – Q1 2024 (PharmaDJ)

4/11/2024Geopolitics Threatens Chinese Biotechs' Hot Out-licensing Biz (Fierce ...

4/11/2024Drugmakers Race to Find Alternative Suppliers as US Cracks Down on Chi...

4/10/2024Biosimilars Coming into Their Own in China, Despite Concerns (Bioworld...

4/9/2024CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Goin...

4/5/2024Foreign Investors Fled Chinese Biotech After the Pandemic. They Still ...

4/3/2024Chinese ADC Investment Boom in Question With China-U.S. R&D Relations ...

4/3/2024What To Know About Jiyoutai - China's First Potential Ozempic Challeng...

3/29/2024NMPA Holds the 2024 National Drug Regulatory Policy and Regulation Wor...

3/29/2024Small Biotechs Reveal Reliance on Chinese CDMOs (BioCentury)

3/29/2024WuXi AppTec Shared US Client's Data with Beijing (Reuters)

3/27/2024BIOSECURE Act May Implicate WuXi-Produced Drugs in the US Market

3/27/2024U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies (WSJ...

3/26/2024China Plays Down Concerns Over State Health Insurance Scheme, But Ques...

3/26/2024Anti-China Bills Portend Massive Blow to Biotech: BioCentury Survey (B...

3/26/2024Chinese Biotechs See Cash Again; Late-stage Assets Most Attractive (th...

3/25/2024Chinese ADC Developers Unveil More Target Combos In Bispecific Drive (...

3/25/2024Lilly CEO Reaffirms Commitment to Chinese Market amid US Threat agains...

3/20/2024China Ranked Top Potential Biopharma Outsourcing Destination (Bioproce...

3/19/2024Perspectives on 2024's Two Sessions (NCUSCR)

3/19/2024Genscript Losses Shrink on Strong Growth for Cancer Cell Therapy (Bamb...

3/18/2024The US and Chinese Biopharma Contractors (Science)

3/15/2024Major Life Sciences Licensing Deal Trends in China in 2023 (Supra)

3/13/2024Navigating China's Biologics Approval And Accelerated Pathways (Clinic...

3/13/2024WuXi Became a Critical Partner to Biopharma Companies. They're Not Rea...

Page:1/7 Total number of articles:184: [First][<<] [1] [2] [3] [4] [5] [>>] [End]